Welcome to the Crane Company First Quarter 2024 Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Jason Feldman, Senior Vice President of Investor Relations, Treasury and Tax. Please, go ahead.

Thank you, operator, and good day, everyone. Welcome to our first quarter 2024 earnings release conference call. On our call this morning, we have Max Mitchell, our Chairman, President and Chief Executive Officer; and Rich Maue, our Executive Vice President and Chief Financial Officer. We'll start off our call with a few prepared remarks, after which we will respond to questions. Just a reminder that the comments we make on this call may include some forward-looking statements. We refer you to the cautionary language at the bottom of our earnings release and also in our annual report, 10-K and subsequent filings pertaining to forward-looking statements. Also during the call, we will be using some non-GAAP numbers, which are reconciled to the comparable GAAP numbers and tables at the end of our press release and accompanying slide presentation, both of which are available on our website at www.craneco.com in the Investor Relations section. Now let me turn the call over to Max.

Thank you, Jason. Good morning, everyone. Thanks for joining the call today. We had another impressive quarter with results outperforming expectations. Adjusted EPS was $1.22, driven by 5% core sales growth, along with strong leading indicators, core orders and backlog, both up 11% compared to last year. We are off to a great start in 2024. Based on that strength, we are raising our full year guidance by $0.20 to a range of $4.75 to $5.05, which reflects a 14% EPS growth at the midpoint. That's a high-confidence guidance that we have direct line of sight to delivering, assuming somewhat muted industrial activity and continued, but gradual, improvement in the aerospace and electronics supply chain. While this is our best thinking today, we believe there may be upside as the year progresses if those 2 assumptions prove conservative. If so, we are structured to meet any unexpected changes in upside demand. There's also a potential upside to guidance from capital deployment if we are successful with further M&A in the quarters ahead. On that front, in addition to our strong first quarter results, I'm pleased to announce that we signed an agreement to acquire CryoWorks as a strategic bolt-on in our Process Flow Technologies segment. Founded in 2009 based in Jurupa Valley, California, CryoWorks is a leading supplier of vacuum-insulated pipe systems for hydrogen and cryogenic applications, which is highly synergistic with the ongoing organic development of our CRYOFLO brand. CryoWorks has an annual sales of approximately $28 million with approximately $5 million of adjusted EBITDA. With a purchase price of $61 million before tax step-up benefits with a net present value of approximately $11 million, we expect that transaction to close at the end of this month. CryoWorks significantly and immediately expands our portfolio of cryogenic products and solutions…

Thank you, Max. But I must say that I think you undersold my excitement and passion, in the words of Ron Burgundy in the movie Anchorman, don't act like you're not impressed. I'm kind of a big deal. People know me. I have many leather-bound book and my apartment smells of rich mahogany. For those who do not know me, I am kidding, but I am embarrassed to say, that I do enjoy that movie. And good morning, everybody. Another strong quarter demonstrating accelerating core growth results with continued excellent performance across all businesses despite some persistent supply chain challenges that continue to impact the broader aerospace and defense industry. Core sales growth of 5% reflects continued strong demand and great execution at Aerospace & Electronics. Adjusted operating profit increased 6%, while that reflects leverage more muted than we typically see in our businesses, it was known and due to expected factors that we previously discussed. First, acquired sales always leverage mathematically at their operating profit margin level in the first year. Second, we have a very challenging comparison at Process Flow Technologies to last year's record 23.4% adjusted operating margin, which I'll discuss more in a minute. Adjusted EPS also beat our expectations, and remember that comparing EPS to the prior year is challenging as our capital structure and related interest expense changed materially after last year's separation transaction. From a quarterly perspective, as I just mentioned, there are also a number of timing differences comparing 2024 to 2023, that flattered the first quarter of last year and created difficult comparisons. Looking at our results another way, our first quarter EPS run rate compared to full year 2023 reflects 14% adjusted EPS growth. Importantly, leading indicators were also strong, with core FX-neutral backlog and orders both up 11% compared…

And the floor is now open for questions. [Operator Instructions] And our first question will come from Matt Summerville with D.A. Davidson.

Maybe, first, if we can start with PFT. Can you talk about how much incremental price capture you're expecting in that business in '24 relative to '23? And then you mentioned specifically North America and China seeing some healthy project activity, could you maybe put a little end market color around that and then touch on, more broadly speaking, what you're seeing in the MRO side of PFT? And then I have a follow-up.

Yes, Matt, just on the first question on pricing and what we expect in '24 relative to 2023, we would expect full year this year to be in the mid-single-digit range, roughly, for overall PFT. I would say that, that's slightly lower than 2023, overall, but still healthy.

On North America and [ help project health ] and so with some of the end market commentary, Matt. Look, as what we told you historically, as we look at historic modeling of the cycles, we predicted that orders were going to go negative in Q3, kind of inflected that point and continue to then recover from there. And then we believe it was just moving to the right. I think what we're realizing, and we're still seeing this play out. I mean, certainly, it's been stronger than we anticipated, not quite as bad as we had forecast based on previous cycles. I think it's unique for this post-COVID environment. And we probably underestimated the impact of some of the reshoring, broadly, that's impacting direct and indirect order strength in chemicals in the Gulf Coast. So right now, with the revised guidance, we're looking at not inflecting as negative as we had anticipated and recovering from here. In terms of the project and MRO strength, I mean there's just a broad-based improvement in projects, overall. North America, in particular, China, to a lesser degree, but stronger than anticipated. Europe hasn't changed significantly. Some of the reasons are expansions, debottlenecking, some reliability improvements. We're even seeing some pull-through in the semiconductor -- semiconductor related, there are chemical applications using erosive corrosive chemicals in semiconductor that we're seeing some general strength there also. But generally, it's coming in a little stronger than we had anticipated, and I think we're feeling a little more bullish.

I would agree. And I would say that maybe bolstering some of what Max mentioned was just our success in some of the share gain initiatives that we continue to have with our new product introductions across the business, Matt.

Perfect.

About a pharmaceutical win, it's things like that, that we continue to -- we make good progress on.

Got it. And then just as a follow-up, I think GE sort of dialed back on their conference call today, the growth outlook for the LEAP engine this year from, I think, 20% to 25% to 10% to 15%. How does that, if at all, kind of impact the outlook for your A&E business? And I guess how closely would your business kind of -- for that program kind of correlate to that sort of growth rate?

Yes. I think what I would say is as it relates to 2024, we don't expect any change for our business relative to any change in outlook for the LEAP. At this point, Matt. Looking out to the extent that it changes a little bit, it would have some impact. But for 2024, we would not expect any. Just given the demand environment that we're in today.

Our next question will come from Scott Deuschle with Deutsche Bank.

Rich, I think hearing you quote Ron Burgundy might end up being the highlight of this earning season.

I'm hoping our earnings is a better highlight.

No, yes, that's true. Very good. Rich, I guess, my first question would be whether you can give us a sense for what the price realizations were this quarter at A&E and PFT separately?

Sure, sure. So on PFT, I would just reiterate around mid-single digit is what we're seeing in the business overall. And at A&E, roughly 1/3 of the growth that we saw in the core growth that we saw in the quarter has been through price with the balance being volumes. Does that help?

Okay. Yes, that's very helpful. And then, Max, I was wondering if you might characterize the kind of broader competitive intensity at PFT right now, particularly relative to [indiscernible] China. I'm just curious, not something I know very much about, but I'm just curious if you're seeing that specific Chinese competitor move up the value chain at all or if the competitive environment is pretty status quo?

[indiscernible] in particular, I don't like to kind of talk about competitors too much. I would say that we're not seeing any dramatic change. Where years ago, we may have been more concerned about Chinese manufacturers entering the U.S. globally, we haven't seen that kind of traction take place. I think we're well positioned, even within China, there's a place for the global manufacturer versus localized spend. And those -- that customer base that values still, the technology, quality, delivery, stability that we bring and differentiate ourselves on that we continue to win, not dramatic shifts, anything that we see significantly within the competitive base within the last year or a couple of years, quite honestly.

Okay. Great. And then, Max, last question, which is do the midsized deals in the pipeline skew at all more toward A&E or more towards PFT or is it relatively well balanced on the midsized deal?

It's balanced right now, Scott.

Our next question will come from Nathan Jones with Stifel.

I'm going to start with a bit of a longer-term question. I know you guys have had a high single-digit kind of organic growth rate target out there over the next several years into the next decade. I'm sure that had a number of these projects like the radar one you're talking about this morning in those and probability weighted on the chances that you'd win them and that they come to fruition. Maybe you can just talk about over the last 2 or 3 years, have things gone better than you expected in that algorithm, in line with what you'd expected, worse than what you'd expected? And has it changed? Has your outlook changed for the potential on some of those future wins that drive that long-term organic growth rate?

Yes. So good question, Nathan. So when we set that 7% to 9% target a few years ago, there was clearly a set of assumptions that we had in mind, whether that was project wins and defense, how we sort things rolling out in commercial, more EV wins -- type wins, the high-power defense and so forth. So what I would say is, since then, we clearly have won a little bit more than we had anticipated in that 7% to 9%. I think every AESA platform that's been out there available for bid and quote when we've -- I think we've won all of them. The other thing, so we've seen more momentum in project wins, I think is the part of the answer. The other part of the answer would be our success on -- and future, I would say, more longer term and runway as it relates to price. So we do see further opportunity there, I would say, relative to when we first set the 7% to 9% growth rate.

I think we'll update on the longer-term vision at Investor Day as well, Nathan.

I wasn't going to actually ask you to go 8 to 10 or 9 to 11 today. I figured we might get that in May or something. While we're all making jokes today, just a question on PFT. Clearly, things have turned a little bit there. Some of the leading indicators, macro leading indicators that we all look at have turned up and are looking better. I think the outlook is -- fundamentally looks a little bit better. And you guys are taking it up a little bit but remaining pretty cautious. Could you talk about the things that keep giving you some caution on the outlook there, what the risks you see to the outlook that maybe keep it where it is and it doesn't move up throughout the year or maybe it even comes in below where you've guided to?

My goodness, the uncertainty just remains what's outside of our control, quite honestly. You have a highly charged political environment. You have wars. We have unknown inflationary environment and Fed action. I mean, there's just a lot of global uncertainty that is, I think, the right reason to be cautious and be prepared for anything. Having said that, what's within our control and what we see immediately, it feels high confidence. I would say that, I see -- if this trend continues, a little downside risk with some upside potential opportunity what could influence that potentially Europe coming back a little stronger, potentially, that's how I'm thinking about it.

Yes. I mean I would echo the -- it's probably -- maybe the inverse of the question is when do we see things -- what would be a positive indicator for us. And it really is more, probably, that's the way we're thinking of things. There could be these things that could go wrong. But European chemical getting better, faster. So to the extent that, that happens, we would see upside to what we've shared today at the midpoint.

And our next question will come from Damian Karas with UBS.

Firstly, I just want to congratulate Jason on your recent promotion. From my perspective, very, very much deserved.

Thank you, Damian. Thanks for the comment. Agree.

No, absolutely. And Rich, maybe it doesn't have to be now, but maybe some time you can just explain to us the history of us on [ Enviago ].

Okay. We'll do.

So let me ask you about aerospace. Sorry if I missed this, but you've talked in the past about unmet demand and I know you're still facing some supply chain bottlenecks. Could you just give us an update on the what -- where you think that unmet demand, the size of it, kind of what it represents and kind of what it would take to maybe see some of those constraints removed?

Yes. Thanks, Damian. So it's still in that $50 million to $60 million range. It's a rough estimate. Remember, this supply chain, we've described, it moved from true supply chain, post-COVID, supplier shortages ramping up, so forth, electrical components. It's improved broadly in terms of just on-time delivery issues to become more general supply chain challenges around everything from capacity to turn over in our supply base, general challenges that moves around. I wouldn't call out any one commodity. I wouldn't call out any one supplier, castings can continue to be problematic over time, things like that. So as we think about this and it's not the same $50 million or $60 million, our customers were not impacting customer deliveries. It moves to the right. But generally, it's in the same. So that's good news as well. So it's not worsening. It's stable, and we continue to see modest improvement, and that's in our guide, which is just continued modest improvement. So to the degree that things can continue to improve, then we would expect to be able to pull some things in a little sooner. If not, I think we feel confident in how we planned and guided so far.

Agree. And Damian, the one thing that I would add is the order strength that we saw in the quarter as well, right? Much of it was beyond '24 delivery, right? So where you might say, well, why isn't that $50 million or $60 million getting bigger. A good portion of what we saw on the way of strength is for delivery in '25 and '26, frankly.

Okay. Great. That's really helpful. And then you gave some commentary around PFT in the end market verticals and regions. Would you possibly be able to just give us some numbers around, okay, so European chemicals and construction was a drag on 1Q sales, like how much of a drag was it? And what are you baking into the full year guide, thinking about that 1% organic growth, like how much of a headwind are you currently factoring in for European chem and construction?

I'll -- let me see if I can tackle what you're asking there. I would say that we're not expecting a lot of the repair and maintenance activity right now to improve significantly in European chemical. Our revised guidance reflects some project activity that's been building, as you know, over the last few quarters that some of it will spill here into the 2024 period, largely in U.S. opportunities, China opportunities. So in terms of the overall guide revision on plus 1%, I would say, it's stable in that maintenance area, MRO area and increasing in chemical North America, China. Jason, would you add anything else?

No. I mean, again, the guidance increase was strength of projects. Specifically on European Chemical, I think we've commented that we expect that down double digits this year.

And our next question comes from [indiscernible] with Bank of America.

On Aerospace & Electronics, could you guys give us some color around how you're thinking about the rest of the year for how long the aftermarket strength can continue for both military and commercial? And if you're seeing even higher pricing being able to get pushed through relative to the whole segment?

Sure. So well, for military, I'll start there. We entered the year with sort of a double-digit guide on where we thought military aftermarket was going to be, just given what we were saying entering the year, I would say that's largely unchanged. We still see really good strength in that end market, whether that's R&O, spares, retrofit, et cetera. On commercial aftermarket, we did have a really robust quarter this quarter in Q1. Some favorable comps help us there as well. And then as we move through the balance of the year, we still aren't seeing an outlook of basically low double digit, which is what we said coming into the year this year. So you'll see the year-over-year as we move forward, be a little bit more muted than what we saw here in Q1, but still pretty strong. From a pricing point of view, we're continuing to seize all those opportunities as you'd expect us to, whether that's through indexing that exists and other opportunities strategically for us to take price up. Jason?

No. I mean on the more immediate growth rate as we progress through the year, just remember to look at the comps, right, the comparisons in the second half are a lot more challenging than the first half. If you look at the fourth quarter, 2 years in a row, 24% in the fourth quarter of '22, 33% up last year. They do get a lot more challenging. But the trend itself on a dollar basis continues to be quite favorable.

[Operator Instructions] And our next question will come from Justin Ages with CJS Securities.

Was just hoping you could give us an update on the hydrogen business that was called out as one of the pillars of growth. Does the recent acquisition fit into that? Or is that going to be a separate business because of the end markets served there?

Yes, great question. Thank you. So it absolutely fits into the current strategy. So we've -- and we'll give an update on Investor Day as well. We previously talked about our investment in the CRYOFLO brand and creating our own vacuum-jacketed pipe as well as valves and fittings and entering into the market. We've got a line of valves. We've already announced a strategic partnership with Chart on some of that. We're getting traction right now with approvals across major gas producers. This is where the focus has been, working on design, starting this business. So we have a site in Conroe, Texas, that is going to be -- was the core CRYOFLO vacuum-jacketed pipe producing facility as we move forward. CryoWorks brings to us immediately a presence on the West Coast. And you tend to see regional strength with the vacuum-jacketed and vacuum-insulated piping systems for hydrogen and cryogenic solutions. What we plan to do is leverage the existing team's sales growth investment and also technology to expand range, expand into still keep the growth into the Texas facility for East Coast and Gulf positioning and continuing to grow and take share at an accelerated rate. So it brings immediate acceleration of our product development initiatives as well as sales expansion for CryoWorks in the vacuum-insulated piping solution, which will then help us in terms of the full solution, valves fittings and vacuum-insulated piping, so very synergistic.

And with no further questions in queue, this does conclude the Q&A portion of today's call. I would like to turn the floor back to Max Mitchell for closing remarks.

Thank you, operator. We had a great start to the year. And looking ahead, we've got a great event planned for May 14, and I hope to see many of you there at our Investor Day, where we will further share our growth strategy for the future. In the words of the late great interior and fashion designer, Iris Apfel, you can't go to the future if you haven't come from the past and past strategic development, deployment and execution has clearly been at the heart of our present performance, and we look forward to explaining our future strategic direction, expectations and path forward for profitable growth in May. Thank you all for your interest in Crane and your time and attention this morning. Have a great day.

Thank you. And this does conclude today's Crane Company First Quarter 2024 Earnings Conference Call. Please disconnect your lines at this time, and have a wonderful day.